Launch of Meropen® for Intravenous Drip Infusion 0.5g (kit)
- Kit preparation of carbapenem antibiotic -
Sumitomo Pharmaceuticals Co., Ltd. today launched Meropen® for Intravenous Drip Infusion 0.5g (kit) (Meropen® (kit)), a carbapenem antibiotic preparation.
A joint development of Sumitomo Pharmaceuticals and Otsuka Pharmaceutical Factory, Inc., the kit preparation features a partitioned double-bag system. The upper bag is filled with Meropen®em tryhydrate 0.5g (titer), and the lower bag 100 ml of saline solution.
Combining an injectable form of the antibiotic and the solution in one kit not only offers medical benefits, such as the prevention of contamination, higher preparation accuracy and avoidance of drug mix-ups, but also increases convenience by easing the burden of preparing the solution and reducing storage space and medical waste.
Meropen® is a carbapenem antibiotic preparation developed by the Company and released in Japan in September 1995 in vials. It exhibits a broad antibacterial spectrum that covers both Gram-positive and Gram-negative bacteria, exerting particularly strong activity against Gram-negative bacteria, including Pseudomonas aeruginosa, Haemophilus influenzae and Enterobacteriaceae. The product is the only carbapenem antibiotic in the world which can be administered on its own, without the need to combine it with a nephrotoxity reducer.
In Europe and North America, the antibiotic is licensed to AstraZeneca PLC of the U.K., which markets it in more than 80 countries. The preparation has taken over some 80% of the U.K. carbapenem antibiotic market. In the U.S., it received FDA approval in 1996 and enjoys high popularity, carrying a recommendation from the National Committee for Clinical Laboratory Standards (NCCLS) as the anti-bacterial of choice for sensitivity examinations.
Sumitomo Pharmaceuticals wishes to contribute to the advancement of medical services by quickly and accurately communicating the benefits of Meropen® and the convenience of the kit preparation to health-care professionals.